GBS GLUCOSE BIOSENSOR SYS

Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC

NEW YORK, March 26, 2024 (GLOBE NEWSWIRE) -- ("INBS" or the "Company") (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that President and CEO, Harry Simeonidis, and CFO, Spiro Sakiris, are scheduled to present at the LD Micro Invitational XIV Investor Conference to be held on April 8-9, 2024 in New York City.

LD Micro Invitational XIV Investment Conference

Dates: April 8-9, 2024

Location: Sofitel New York, NYC

Presentation: 12:00 p.m. ET on April 9, 2024

Webcast:

Management will be available during the event for 1x1 meetings with the investment community. To schedule a meeting please reach out to your LD Micro representative or KCSA Strategic Communications by emailing .

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. Additionally, the Company's biosensor platform has the potential to test for up to 130 indications, ranging from glucose to immunological conditions and communicable diseases. The Company's current customer segments include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit: 

Company Contact:

Intelligent Bio Solutions Inc.



 | 

Investor & Media Contact:

Valter Pinto, Managing Director

KCSA Strategic Communications

PH: (212) 896-1254



EN
26/03/2024

Underlying

GBSGLUCOSE BIOSENSOR SYS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GLUCOSE BIOSENSOR SYS

 PRESS RELEASE
Free
GBS GLUCOSE BIOSENS...

Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue...

Intelligent Bio Solutions Reports Record Fiscal Second Quarter Revenue Growth of 48% with Reader Sales Surging 104% Year-Over-Year First half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year  Reader sales more than double to 104% year-over-year for the second quarter, demonstrating razor-razorblade model momentum Gross profit margins for first half fiscal 2026 increased 10% year-over-year to 49%, reflecting improved operational efficiency Current assets balance of $12.17 million as of December 31, 2025, including $9.40 million receivable in connection with the private plac...

February 12, 2026 1 EN
 PRESS RELEASE
Free
GBS GLUCOSE BIOSENS...

Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026...

Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Co...

February 5, 2026 1 EN
 PRESS RELEASE
Free
GBS GLUCOSE BIOSENS...

Intelligent Bio Solutions Initiates Additional Clinical Studies for FD...

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market Clinical studies designed to support FDA clearance and planned commercial launch into the world’s largest drug screening market  Company anticipates full data analysis by the end of March 2026; data to be incorporated into FDA 510(k) submission package NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasi...

January 28, 2026 1 EN
 PRESS RELEASE
Free
GBS GLUCOSE BIOSENS...

Intelligent Bio Solutions Announces Closing of $10.0 Million Private P...

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the closing of its previously announced private placement with two healthcare focused institutional investors priced at-the-market under Nasdaq rules of 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to ...

January 2, 2026 1 EN
 PRESS RELEASE
Free
GBS GLUCOSE BIOSENS...

Intelligent Bio Solutions Announces $10.0 Million Private Placement Pr...

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- (“INBS” or the “Company”) (Nasdaq: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it entered into a securities purchase agreement with two healthcare focused institutional investors to issue, in a private placement priced at-the-market under Nasdaq rules, 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof), Series K-1 warrants to purchase up to ...

December 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch